I have no qualms with releasing a subset of the data that is properly and irreversibly anonymized. But you have to keep in mind that by introducing “randomness”

I have no qualms with releasing a subset of the data that is properly and irreversibly anonymized. But you have to keep in mind that by introducing “randomness” into the dataset, you limit it’s usefulness to check to make sure the statistics match up with the study’s official topline results. Furthermore, the FDA submission dataset is essentially a database with dozens of tables each with often hundreds of columns. It’s a LOT of data, with exponential complexity to make sure all the right fields are redacted. There’s also the point that pharma companies are under no obligation to release this data. It’s generally considered proprietary. That said, due to the substantial amount of government funding provided to the development of the vaccine, I think we should be entitled to this information.